“Biological Drug API Manufacturing market set to grow to $7.3bn by 2022” says pharmaceutical analyst.

06 July 2018
Pharma

Visiongain’ has launched a new pharma report Biological Drug API Manufacturing Services World Industry and Market Predictions 2018-2028: Mammalian Cell Cultures, Microbial Fermentations, Other Expression Systems, Human Growth Hormones, Insulin, Interferons, Monoclonal Antibodies, Vaccines

The growth of the biosimilars market in the EU and the rise of generics will have a big effect on the biotech manufacturing services market. Additionally, as the patent cliff effect takes hold and many blockbuster biologics are scheduled to lose patent protection by 2019, companies will be consolidating to take advantage of this opportunity. Consolidation as a strategy gives not only manufacturing capabilities, but access to cutting-edge technology and helps foster and establish relationships that can be used to enter new markets. It is difficult for a company to determine what manufacturing capacity requirements will be in demand. The next 10 years of biotech manufacturing is estimated to have a shortfall in capacity, which is why some companies have begun plans to expand while for others, outsourcing is critical. Outsourcing as a strategy to reduce costs and increase efficiency can be a strength for biopharmaceutical companies. This trend in outsourcing will shift from the traditional model of using EU and US CMOs to outsourcing from lower emerging market CMOs, especially in Asia.

The lead analyst of the report commented “Concerns over quality and drug recalls will play a major role in biotech CMO selection in this forecast period, Visiongain believes. Selecting a CMO with significant experience in manufacturing a particular drug type will lead to more demand for the most established and largest CMOs. Although CMOs in emerging markets can offer lower cost manufacturing, a lack of experience with biopharmaceutical products will limit the level of offshoring by US and EU-based biotech’s in this forecast period unless they can increase their adherence to standard regulations.”

Leading companies featured in the report include Boehringer Ingelheim BioXcellence, Celltrion, DSM Biologics, Lonza, Samsung BioLogics, Cytovance Biologics, Fujifilm Diosynth Biotechnologies, Abbvie, GSK, Novartis

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 207 336 6100

About visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-to-business reports cusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

“Global Ophthalmic Drugs market set to grow to $33bn by 2024” says new Visiongain report

The market for ophthalmic drugs is a growing one.

17 June 2019

Read

“Generic Drugs market set to grow to $424bn by 2024” says new Visiongain report

Visiongain believes the market will see more traditional pharma companies beginning to embrace the generic business in order to take advantage of higher growth rates in this area.

14 June 2019

Read

“Global Precision Cancer Diagnostic Tests market set to grow to $21.3bn by 2024” says new Visiongain report

The market players are increasingly focusing on precision therapies where drug and precision tests are developed simultaneously.

06 June 2019

Read

“Global Antifungal Drugs market set to grow to $17bn by 2024” says new Visiongain report

Market penetration and adoption of new technologies entering the market for antifungal drugs will be crucial for market growth.

04 June 2019

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever